期刊文献+

奥沙利铂联合氟尿嘧啶及甲酰四氢叶酸治疗晚期大肠癌近期疗效分析 被引量:1

Clinical study of oxaliplatin plus 5-FU/CF in treatment of advanced colorectal cancer
在线阅读 下载PDF
导出
摘要 目的 :评价国产奥沙利铂 (oxaliplatin ,L OHP)联合氟尿嘧啶及甲酰四氢叶酸 (CF)治疗大肠癌的疗效和毒副反应。方法 :2 8例晚期大肠癌患者 ,予国产L OHP 12 0mg/m2 ,静脉滴入 ,持续 2h ;CF 15 0mg/m2 ,静脉滴入 ,持续 2h ;5 -氟尿嘧啶 ( 5 FU ) 5 0 0mg/m2 ,静脉滴入 ,持续 >4h ,于CF滴完后用。每 3周重复 1次 ,用药 2个周期后评价疗效。结果 :2 8例患者中 ,无完全缓解 (CR) ,部分缓解 (PR) 9例 ,稳定 (SD) 12例 ,进展 (PD) 7例 ,总有效率(RR ,CR +PR) 3 2 1% ( 9/2 8) ,中位无进展生存期 6 7个月 ,中位生存期 9 8个月。毒副反应主要是末梢神经毒性、恶心呕吐、骨髓抑制及静脉炎等 ,患者均可耐受。结论 :国产L OHP联合 5 FU OBJECTIVE:To evaluate the therapeutic effect and toxicity of oxaliplatin (L-OHP) plus 5-FU/CF in advanced colorectal cancer.METHODS:Twenty-eight patients with advanced colorectal cancer received L-OHP plus 5-FU/CF.L-OHP 120 mg/m 2 was administered,iv infusion for two hours,leucovorin (CF)150 mg/m 2,iv infusion for 2 hours,followed by 5-FU 500 mg/m 2 iv infusion over a period of 4 hours.This regimen was repeated every 3 weeks.RESULTS:Among 28 patients,there were CR 0,PR 9,SD 12,PD 7.An overall response rate (CR+PR) was 32.1%,median time to progress (TTP) 6.7 months and median survival 9.8 months.The major toxicity and side effects were nausea and vomiting,neurosensory toxicity,neutropenia and peripheral phlebitis,but they were acceptable.CONCLUSION:The combinatian of oxaliplatin and 5-FU/CF is an effective and tolerable regimen for treatment of advanced colorectal cancer.
出处 《肿瘤防治杂志》 2004年第3期303-304,310,共3页 China Journal of Cancer Prevention and Treatment
关键词 大肠 结肠直肠肿瘤/药物疗法 奥沙利铂/治疗应用 5-氟尿嘧啶/治疗应用 甲酰四氢叶酸/治疗应用 药物疗法 联合 large,intestine colorectal neoplasms/drug therapy oxaliplatin/therapy use 5-fluarouracil/therapy use leucovorin/therapy use drug therapy,combination
  • 相关文献

参考文献5

  • 1孙燕,管忠震,金懋林,李维廉,李丽庆,石廷章,周立中,隋广杰,许立功,宋恕平,许德凤,李容,李扬,黄富麟,张嘉庆,张和平,鞠利雅.奥沙利铂单药或与氟尿嘧啶-甲酰四氢叶酸联合应用治疗晚期大肠癌Ⅱ期临床试用报告[J].癌症,1999,18(3):237-240. 被引量:344
  • 2Maindrault Goebel F,de-Gramout A, Louvet C,et al. High t-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for m etastatic colorectal cancer (FOLFOX 7) [J]. Eir J Cancer, 2001,37 (8)
  • 3Raymond E,Faivre S,Woynarowski J M,et al. Oxaliplatin:mechanism of action and antineoplastic activity[J]. Semon Oncol, 1998,25(2 Suppl 5):4--12.
  • 4Diaz-Rubio E,Sastre J,Zaniboni A,et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients:a phase Ⅱ multicentric study[J]. Ann Onco1,1998,9(1) : 105- 108.
  • 5孙燕 周际昌.临床肿瘤内科手册[M](第3版)[M].北京:人民卫生出版社,1996.33.

二级参考文献2

共引文献419

同被引文献26

  • 1朱春平,林岩,陆晓东,刘国建.持续静脉滴入低剂量5-FU联合亚叶酸钙和奥沙利铂治疗晚期结直肠癌疗效观察[J].中华肿瘤防治杂志,2006,13(1):77-77. 被引量:2
  • 2Wen-Sy Tsai. Impact of chemotherapy-related prognostic factors on long- term survival in patients with stage III colorectal cancer after curative resection[J]. Int J Clin Oncol. DOI 10. 1007/s10147-011-0370-8.
  • 3Bleiberg H. Oxaliplatin (L-OHP) : a new reality in colorectal cancer [J]. Br J Cancer,1998,77(Suppl 4) : 1 -3.
  • 4Venook A P. Epidermal. growth factor receptor-targeted treatment for advanced colorectal carcinoma [ J ]. Cancer, 2005, 103 ( 2 ) : 2435 - 2446.
  • 5Maria J Lamas. Anti-EGFR therapy in first-line colorectal cancer[ J ].. Expert Rev. Anticancer Ther,2011,11 (10) : 1499 - 1503.
  • 6Georgios V. Koukourakis. Targeted therapy with bevaeizumab ( Avas- tin) for metastatic colorectal cancer[ J]. Clin Transl Onco1,2011,13 : 710 -714.
  • 7Hurwitz HI, Fehrenbacher L, Hainsworth JDet a1(2005 ) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer [ J]. J Clin Oncol, 2010,23: 3502 - 3508.
  • 8Fisher GA,Kuo T,Cho CD. A phase II study of gefitinib in combina- tion with FOLFOX-4(IFOX) in patients with unresectable or metastat- ic colorectal cancer [ J ]. Proc "Am Soc Oncol, 2004, 22 ( 14 ) : 3514 -3516.
  • 9Lockhart AC, C ropp GF, Berlin JD, et al. Phase I/pilot study of SU5416(semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer[ J]. Am JC lin On- co,1 2006,29(2) : 109 - 115.
  • 10Raymond E, Faivre S, Vera K, et al. Final results of a phase and phar- macokinetic study of SU11248, a novel multi-target tyrosine kinase in- hibitor,in patients with advanced cancers[ J]. Proc Am Soc C lin On- col ,2003,22 : 192.

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部